🔗 Share this article

An underground economy for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.

Experimental Treatment Gaining Popularity Online

The experimental drug, which is still in clinical trials, is being promoted by social media influencers for its alleged fat-burning effects. Followers are urged to message these profiles directly for supplier links, while also receiving promotional offers.

Active Trade on Social Networks

Separately, a flourishing market exists on messaging services, where communities with thousands of members share “before and after” photos, injection guides and claims of rapid British shipping. Sellers market the substance there before directing buyers to other platforms for transactions.

Understanding The Experimental Drug

This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals lose up to 25% of their total weight. Nicknamed the “triple G”, the substance is being hailed online as the next Ozempic.

Medical Experts Express Concerns

Nevertheless, physicians and pharmacists have cautions that the distribution of what is still an unlicensed medication in the UK is a cause for concern and could result in individuals injecting products of unknown origin.

Several experts stated the popularity for the experimental drug could be linked to the rising cost of licensed weight loss treatments such as Mounjaro.

Legal Position and Enforcement

Marketing the unapproved drug on TikTok or Telegram is illegal in the UK, as it is an unlicensed medication that cannot be promoted or supplied for personal consumption under the British medical regulations.

Several influencers try to sidestep the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but promotion and supply can still violate pharmaceutical, marketing, and customer laws, potentially leading to penalties, legal action or prison.

Platform Response and Content Removal

According to the social media company, the service has taken down problematic content and banned associated keywords and search suggestions. The company stated it was dedicated to maintaining the platform safe and investing in strengthening compliance measures.

Online Marketplace Activities

Investigations also discovered groups with up to 9,000 members marketing retatrutide using the platform's built-in search feature, which operates like a online catalog. Entering “retatrutide” instantly brings up groups with thousands of users, populated with photos of weight loss, positive reviews and detailed guides for preparing or administering at home.

After minutes of joining one community, a vendor posted contact information, where the majority of transactions occur. The seller provided an instruction manual and guaranteed delivery within two days. When asked whether the substance was authentic, one vendor said: “You can’t be sure.” Another shared a image of a supposed testing documentation. Not one inquired about body mass, health issues or previous experience.

Product Information and Pricing

Within these communities, posts show black plastic parcels with postal service labels, claiming to include fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, mixed at home with purified liquid, or pre-filled injectors usually priced at £160 for 20mg. When questioned how long a injector should last, vendors give conflicting responses ranging from a several days to “depends on your body”.

Platform Moderation and Security Measures

A spokesperson for the messaging service said it regularly monitored harmful content on its service including content that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are administering substances they cannot confirm. Although the research behind retatrutide is sound, these digital products may not include what they advertise,” stated a pharmacy expert, the director of pharmacy at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to recent cost increases for authorized weight-loss medications such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But counterfeit treatments are extremely risky. You cannot know what’s contained or whether the conditions they were made in was sterile,” she said.

Her staff has previously seen patients harmed by self-injection from unverified sources. “We recognize the frustration, but buying from Telegram or WhatsApp is gambling with your well-being,” stated the doctor. “These materials could be impure or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for human use,” they explained, noting that any product “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may subject users to possibly serious medical dangers”.